产品
编 号：F753683
产品类型
规格
价格
是否有货
500μg
询价
询价
1mg
询价
询价
结构图
CAS No: 2552814-07-8
产品详情
生物活性：
Latikafusp (AMG 256) is a bifunctional fusion protein comprising a PD-1-targeting antibody and IL-21 mutein designed to deliver IL-21 pathway stimulation to PD-1+ cells. Latikafusp is designed to prime and extend the activity of cytotoxic and memory T cells and induce anti-tumor immunity. Latikafusp has the potential for solid tumors research.Latikafusp may lead to the development of immunogenicity-mediated responses.
体内研究：
Latikafusp (5 mg/kg; 在第 1 天和第 15 天用药; i.v.) 让 cynomolgus monkeys 出现了较强的免疫原性反应和超敏反应。Latikafusp (10, 30 mg/kg; 三周内每周服用一次; i.v.) 可以激活经典和替代补体途径。Latikafusp (10, 30 mg/kg; 周内每周服用一次 i.v.) 让所有剂量组的 cynomolgus monkeys 均表现出强烈的抗体反应，提示该药物具有较高的免疫原性。Animal Model:Cynomolgus monkeys
Dosage:5 mg/kg; administered on days 1 and 15
Administration: i.v.
Result:Elicited a strong immunogenic response in all animals, as evidenced by the presence of anti-Latikafusp IgG antibodies on days 15 and 25 following the initial dose administration. Compared to the 22D4 group alone, the antibody response was significantly higher.
Animal Model:Cynomolgus monkeys
Dosage:10, 30 mg/kg; Weekly doses over three weeks
Administration: i.v.
Result:Induced the development of anti-Latikafusp IgG antibodies in all animals by day 19, demonstrating a strong immune response to the therapeutic protein.Administration in high doses led to severe adverse reactions and immunogenic complications, underscoring critical safety concerns associated with its use.
Animal Model:Cynomolgus monkeys
Dosage:0, 6, 30, or 150 mg/kg; Weekly doses over four weeks
Administration: i.v.
Result:At the highest dose of 150 mg/kg, caused severe clinical signs in animals, including weakness, petechiae, hypothermia, and dehydration, which led to the unscheduled euthanasia of several animals.Additionally, at high doses was linked to immunogenicity-related complications, such as thrombocytopenia and consumptive coagulopathy.
Latikafusp (AMG 256) is a bifunctional fusion protein comprising a PD-1-targeting antibody and IL-21 mutein designed to deliver IL-21 pathway stimulation to PD-1+ cells. Latikafusp is designed to prime and extend the activity of cytotoxic and memory T cells and induce anti-tumor immunity. Latikafusp has the potential for solid tumors research.Latikafusp may lead to the development of immunogenicity-mediated responses.
体内研究：
Latikafusp (5 mg/kg; 在第 1 天和第 15 天用药; i.v.) 让 cynomolgus monkeys 出现了较强的免疫原性反应和超敏反应。Latikafusp (10, 30 mg/kg; 三周内每周服用一次; i.v.) 可以激活经典和替代补体途径。Latikafusp (10, 30 mg/kg; 周内每周服用一次 i.v.) 让所有剂量组的 cynomolgus monkeys 均表现出强烈的抗体反应，提示该药物具有较高的免疫原性。Animal Model:Cynomolgus monkeys
Dosage:5 mg/kg; administered on days 1 and 15
Administration: i.v.
Result:Elicited a strong immunogenic response in all animals, as evidenced by the presence of anti-Latikafusp IgG antibodies on days 15 and 25 following the initial dose administration. Compared to the 22D4 group alone, the antibody response was significantly higher.
Animal Model:Cynomolgus monkeys
Dosage:10, 30 mg/kg; Weekly doses over three weeks
Administration: i.v.
Result:Induced the development of anti-Latikafusp IgG antibodies in all animals by day 19, demonstrating a strong immune response to the therapeutic protein.Administration in high doses led to severe adverse reactions and immunogenic complications, underscoring critical safety concerns associated with its use.
Animal Model:Cynomolgus monkeys
Dosage:0, 6, 30, or 150 mg/kg; Weekly doses over four weeks
Administration: i.v.
Result:At the highest dose of 150 mg/kg, caused severe clinical signs in animals, including weakness, petechiae, hypothermia, and dehydration, which led to the unscheduled euthanasia of several animals.Additionally, at high doses was linked to immunogenicity-related complications, such as thrombocytopenia and consumptive coagulopathy.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备